11:20 AM EST, 02/04/2025 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) said Tuesday it has completed enrollment in the phase 2 trial of lorundrostat for the treatment of hypertension in subjects with chronic kidney disease and albuminuria.

The clinical-stage biopharmaceutical company said it continues to expect topline data from the trial in Q2 of 2025.

Price: 9.92, Change: -0.01, Percent Change: -0.10